<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02765347</url>
  </required_header>
  <id_info>
    <org_study_id>2016-T1DM</org_study_id>
    <nct_id>NCT02765347</nct_id>
  </id_info>
  <brief_title>The Effects of Metformin on Glycemic Control and Insulin Sensitivity in Adolescents With T1DM</brief_title>
  <official_title>The Effects of Metformin on Glycemic Control and Insulin Sensitivity in Adolescents With T1DM: A Randomized, Cross-over, Prospective Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Third Affiliated Hospital, Sun Yat-Sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Third Affiliated Hospital, Sun Yat-Sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators intends to carry out a randomized, cross-over, prospective study which will
      last 48 weeks in youth with T1DM followed up by the center. The purpose is to observe the
      effects of metformin on glycemic control and insulin sensitivity in adolescents with T1DM
      based on insulin therapy by using 72h CGMS and hyperinsulinemic euglycemic clamps.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2016</start_date>
  <completion_date type="Actual">January 2018</completion_date>
  <primary_completion_date type="Actual">January 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HbA1c</measure>
    <time_frame>half one year</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Diabetes Mellitus, Type 1</condition>
  <arm_group>
    <arm_group_label>Metformin and Insulin</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>MDI or CSII plus metformin (initially starting dosage with 0.5g qd, then gradually increasing to 0.5g bid or tid) for 24 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Insulin</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Accept insulin for 24 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>For arm 1, accept MDI or CSII plus metformin (initially starting dosage with 0.5g qd, then gradually increasing to 0.5g tid) for 24 weeks.</description>
    <arm_group_label>Metformin and Insulin</arm_group_label>
    <other_name>Glucophage</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin</intervention_name>
    <description>For arm 2, just accept insulin for 24 weeks</description>
    <arm_group_label>Insulin</arm_group_label>
    <other_name>CSII or MDI</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Type 1 diabetes mellitus;

          2. Age≥12 yr;

          3. Tanner sexual maturation rating 2-5;

          4. HbA1c levels: 7.5%-10%;

          5. MDI or CSII ≥6 months;

          6. Insulin dose ≥ 0.8U/kg before the enrollment，and the dosage is stable at least ＞1
             month（dosage change&lt;10%）.

        Exclusion Criteria:

          1. Serious acute and chronic complications associated with diabetes;

          2. Repeated and serious hypoglycemia episodes repeatedly;

          3. Hepatic function damage (ALT≥2.5 times higher than the upper limit of the normal
             accepted range);

          4. Moderate to advanced renal impairment (calculated according to MDRD equation:
             eGFR&lt;60ml/min/1.73m2);

          5. Clinically significant heart attacks: myocardial infarction,
             arrhythmia，II-III°AVB，unstable angina，decompensated HF（NYHA III~IV;

          6. Female patients who have a sex life and are not willing to use contraceptive methods;

          7. Pregnancy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wen Xu</last_name>
    <role>Principal Investigator</role>
    <affiliation>Associated professor</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Third Affliated Hospital of Sun Yat-sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510630</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 14, 2016</study_first_submitted>
  <study_first_submitted_qc>May 4, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 6, 2016</study_first_posted>
  <last_update_submitted>April 10, 2018</last_update_submitted>
  <last_update_submitted_qc>April 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 12, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Third Affiliated Hospital, Sun Yat-Sen University</investigator_affiliation>
    <investigator_full_name>Wen Xu</investigator_full_name>
    <investigator_title>Associated Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

